Abbott receives FDA clearance for commercially available TBI blood test

We are very happy to announce that Abbott has received FDA clearance for what will be the first commercially available laboratory traumatic brain injury (TBI) blood test, making it widely available to hospitals in the United States. The test, which runs on Abbott's Alinity® i laboratory instrument, will provide clinicians with an objective way to quickly assess individuals with mild TBIs, also known as concussions.

For nearly a decade, TRACK-TBI has enjoyed a productive collaboration with Abbott, fueled by our shared mission to advance precision and efficient diagnosis of TBI. The constellation of TRACK-TBI clinical research sites spread across the U.S. has been pivotal in developing this tool and were the first to demonstrate how this TBI blood test can be used for the benefit of TBI patients in clinical care.

To read more, click <<here>>